Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC PatientsIlaria Grazia Zizzari, Chiara Napoletano, Aurelia Rughetti et al.|Journal of Personalized Medicine|2020Cited by 44
Immunohistochemical Characterization of Immune Infiltrate in Tumor Microenvironment of GlioblastomaHassan Rahimi, Aurelia Rughetti, Simone Minasi et al.|Journal of Personalized Medicine|2020Cited by 38
IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137+T-cellsAlessio Ugolini, Marianna Nuti, Ilaria Grazia Zizzari et al.|EBioMedicine|2020Cited by 17
Immunomodulatory effects of tyrosine kinase inhibitors (TKIs) in renal cell carcinoma (RCC) patients.Marianna Nuti, Paolo Marchetti, Ilaria Grazia Zizzari et al.|Journal of Clinical Oncology|2017Cited by 5
4P IgM-rheumatoid factor as a novel biomarker for a reduced survival in anti-PD-1 treated NSCLC patients through the decrease of CD137+ T-cellsAlessio Ugolini, Marianna Nuti, Ilaria Grazia Zizzari et al.|Annals of Oncology|2020Cited by 2